title: Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.
abstract: OBJECTIVE
  To determine the ability of dynamic contrast enhanced (DCE-MRI) to predict pathological complete response (pCR) after preoperative chemotherapy for rectal cancer.
  
  
  METHODS
  In a prospective clinical trial, 23/34 enrolled patients underwent pre- and post-treatment DCE-MRI performed at 1.5T. Gadolinium 0.1 mmol/kg was injected at a rate of 2 mL/s. Using a two-compartmental model of vascular space and extravascular extracellular space, K(trans), k(ep), v(e), AUC90, and AUC180 were calculated. Surgical specimens were the gold standard. Baseline, post-treatment and changes in these quantities were compared with clinico-pathological outcomes. For quantitative variable comparison, Spearman's Rank correlation was used. For categorical variable comparison, the Kruskal-Wallis test was used. P ≤ 0.05 was considered significant.
  
  
  RESULTS
  Percentage of histological tumour response ranged from 10 to 100%. Six patients showed pCR. Post chemotherapy K(trans) (mean 0.5 min(-1) vs. 0.2 min(-1), P = 0.04) differed significantly between non-pCR and pCR outcomes, respectively and also correlated with percent tumour response and pathological size. Post-treatment residual abnormal soft tissue noted in some cases of pCR prevented an MR impression of complete response based on morphology alone.
  
  
  CONCLUSIONS
  After neoadjuvant chemotherapy in rectal cancer, MR perfusional characteristics have been identified that can aid in the distinction between incomplete response and pCR.
  
  
  CONCLUSIONS
  Dynamic contrast enhanced (DCE) MRI provides perfusion characteristics of tumours. These objective quantitative measures may be more helpful than subjective imaging alone Some parameters differed markedly between completely responding and incompletely responding rectal cancers. Thus DCE-MRI can potentially offer treatment-altering imaging biomarkers.
authors.affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. gollubm@mskcc.org
authors.forename: M J
authors.initials: MJ
authors.lastname: Gollub
authors.forename: D H
authors.initials: DH
authors.lastname: Gultekin
authors.forename: O
authors.initials: O
authors.lastname: Akin
authors.forename: R K
authors.initials: RK
authors.lastname: Do
authors.forename: J L
authors.initials: JL
authors.lastname: Fuqua
authors.forename: M
authors.initials: M
authors.lastname: Gonen
authors.forename: D
authors.initials: D
authors.lastname: Kuk
authors.forename: M
authors.initials: M
authors.lastname: Weiser
authors.forename: L
authors.initials: L
authors.lastname: Saltz
authors.forename: D
authors.initials: D
authors.lastname: Schrag
authors.forename: K
authors.initials: K
authors.lastname: Goodman
authors.forename: P
authors.initials: P
authors.lastname: Paty
authors.forename: J
authors.initials: J
authors.lastname: Guillem
authors.forename: G M
authors.initials: GM
authors.lastname: Nash
authors.forename: L
authors.initials: L
authors.lastname: Temple
authors.forename: J
authors.initials: J
authors.lastname: Shia
authors.forename: L H
authors.initials: LH
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D003287:Contrast Media; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003287:Contrast Media; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D019786:Gadolinium DTPA; D002955:Leucovorin; D005472:Fluorouracil
references.citation: Pharmacol Rev. 1951 Mar;3(1):1-41
references.pmid: 14833874
references.citation: Br J Radiol. 2005 Oct;78(934):934-8
references.pmid: 16177017
references.citation: Cancer. 2008 Jul 1;113(1):57-64
references.pmid: 18442099
references.citation: Ann Oncol. 2009 Sep;20(9):1589-1595
references.pmid: 19491285
references.citation: J Magn Reson Imaging. 2007 Sep;26(3):662-71
references.pmid: 17729365
references.citation: Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
references.pmid: 15383798
references.citation: Magn Reson Med. 1991 Feb;17(2):357-67
references.pmid: 2062210
references.citation: Lancet Oncol. 2007 Mar;8(3):245-55
references.pmid: 17329195
references.citation: Cancer Res. 1998 Apr 1;58(7):1408-16
references.pmid: 9537241
references.citation: Am J Surg Pathol. 2004 Feb;28(2):215-23
references.pmid: 15043311
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1309-15
references.pmid: 16125874
references.citation: Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):99-107
references.pmid: 18407433
references.citation: Onkologie. 2009 Mar;32(3):86-93
references.pmid: 19295245
references.citation: Br J Surg. 2001 Dec;88(12):1628-36
references.pmid: 11736977
references.citation: Top Magn Reson Imaging. 2004 Feb;15(1):41-57
references.pmid: 15057172
references.citation: Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):60-6
references.pmid: 18922649
references.citation: Radiology. 2000 Nov;217(2):385-91
references.pmid: 11058632
references.citation: Dis Colon Rectum. 2010 Dec;53(12):1692-8
references.pmid: 21178866
references.citation: J Magn Reson Imaging. 2007 Apr;25(4):796-805
references.pmid: 17347990
references.citation: Br J Surg. 2006 Aug;93(8):992-1000
references.pmid: 16673354
references.citation: Cancer Res. 2001 Mar 15;61(6):2513-6
references.pmid: 11289123
references.citation: J Clin Oncol. 2010 Jan 10;28(2):207-14
references.pmid: 19949018
references.citation: Colorectal Dis. 2009 Mar;11(3):249-53
references.pmid: 18513192
references.citation: Crit Care. 2004 Jun;8(3):196-9
references.pmid: 15153238
references.citation: Physiol Chem Phys Med NMR. 1984;16(2):167-72
references.pmid: 6505043
references.citation: Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):761-8
references.pmid: 15936557
references.citation: Nat Med. 2004 Feb;10(2):145-7
references.pmid: 14745444
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references.pmid: 16246976
references.citation: Radiology. 2005 Mar;234(3):785-92
references.pmid: 15734934
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):400-8
references.pmid: 19733445
references.citation: J Nucl Med. 2006 Jan;47(1):14-22
references.pmid: 16391182
references.citation: J Magn Reson Imaging. 1999 Sep;10(3):223-32
references.pmid: 10508281